2025--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has approved memantine/donepezil 14-10 mg and 28-10 ...
In trading on Monday, shares of Amneal Pharmaceuticals Inc (Symbol: AMRX) crossed below their 200 day moving average of $7.76, changing hands as low as $7.68 per share. Amneal Pharmaceuticals Inc ...
Reaffirms Annual Forecasts Amneal Pharmaceuticals Q3 sales rose 13% to $702.47 million, beating estimates. EPS hit $0.16, above consensus, driven by strong launches and specialty growth.
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the five brokerages that are currently covering the stock, Marketbeat ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback